Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7,363
Recruiting: 3,965
Ph III recruiting: 535
Growth YoY: +10.3%
Industry share: 25%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3,404)

clinicaltrialsPublishedShowing 101–150 of 1,036 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05081609	A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe)	active not recruiting	Phase 1 / Phase 2	320	Ascendis Pharma Oncology Division A/SINDUSTRY	10	Sep 11, 2026	clinicaltrials
NCT05186974	Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)(EVOKE-02)	active not recruiting	Phase 2